報價延遲最少15分鐘:2025/07/20 13:03 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.91 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.73/-3.15
|
|
企業價值
3.13B
|
| 資產負債 |
|
每股賬面淨值
4.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 13:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates. |
